Today's Pre-Market Mover With Heavy Volume: Novo Nordisk A/S (NVO)
Trade-Ideas LLC identified
(
) as a pre-market mover with heavy volume candidate. In addition to specific proprietary factors, Trade-Ideas identified Novo Nordisk A/S as such a stock due to the following factors:
- NVO has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $115.0 million.
- NVO traded 265,414 shares today in the pre-market hours as of 8:11 AM, representing 12.8% of its average daily volume.
EXCLUSIVE OFFER: Get the inside scoop on opportunities in NVO with the Ticky from Trade-Ideas. See the FREE profile for NVO NOW at Trade-Ideas
More details on NVO:
Novo Nordisk A/S, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Biopharmaceuticals. The stock currently has a dividend yield of 1%. Currently there are 2 analysts that rate Novo Nordisk A/S a buy, no analysts rate it a sell, and 2 rate it a hold.
The average volume for Novo Nordisk A/S has been 1.6 million shares per day over the past 30 days. Novo Nordisk A/S has a market cap of $142.2 billion and is part of the health care sector and drugs industry. Shares are up 28.2% year-to-date as of the close of trading on Tuesday.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
Analysis:
rates Novo Nordisk A/S as a
. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, notable return on equity, expanding profit margins and increase in net income. We feel its strengths outweigh the fact that the company shows weak operating cash flow.
Highlights from the ratings report include:
- The revenue growth came in higher than the industry average of 3.4%. Since the same quarter one year prior, revenues rose by 25.9%. Growth in the company's revenue appears to have helped boost the earnings per share.
- Looking at where the stock is today compared to one year ago, we find that it is not only higher, but it has also clearly outperformed the rise in the S&P 500 over the same period. Although other factors naturally played a role, the company's strong earnings growth was key. Turning our attention to the future direction of the stock, it goes without saying that even the best stocks can fall in an overall down market. However, in any other environment, this stock still has good upside potential despite the fact that it has already risen in the past year.
- Current return on equity exceeded its ROE from the same quarter one year prior. This is a clear sign of strength within the company. Compared to other companies in the Pharmaceuticals industry and the overall market, NOVO NORDISK A/S's return on equity significantly exceeds that of both the industry average and the S&P 500.
- The gross profit margin for NOVO NORDISK A/S is currently very high, coming in at 85.64%. It has increased from the same quarter the previous year. Along with this, the net profit margin of 31.29% significantly outperformed against the industry average.
- The net income growth from the same quarter one year ago has significantly exceeded that of the S&P 500 and the Pharmaceuticals industry. The net income increased by 37.4% when compared to the same quarter one year prior, rising from $914.62 million to $1,256.46 million.
- You can view the full Novo Nordisk A/S Ratings Report.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.